Financial Results for the quarter ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kerala Ayurveda Limited reported wider losses for Q3FY26 with standalone revenue from operations rising to Rs. 2,206.52 lakhs (vs Rs. 1,935.25 lakhs in Q3FY25), but standalone loss after tax deepened to Rs. 347.32 lakhs (vs Rs. 8.21 lakhs loss). For 9MFY26, standalone PAT loss stood at Rs. 680.68 lakhs vs Rs. 191.59 lakhs loss a year ago. On a consolidated basis, 9MFY26 revenue grew modestly to Rs. 9,640.88 lakhs (vs Rs. 8,901.29 lakhs), but loss after minority interest was Rs. 1,148.93 lakhs against a small profit of Rs. 106.91 lakhs in 9MFY25. Statutory auditors (G Joseph & Associates) issued an unmodified limited review opinion. Alongside results, the Board approved a preferential issue of 6,30,000 equity shares at Rs. 327.99 to promoter-group entity Katra Holding Pvt Ltd to convert an outstanding unsecured loan of Rs. 20.66 crores into equity.
The stock remains loss-making with losses widening sharply even as revenues grow, suggesting cost pressures (employee and finance costs have risen materially). Shareholders should note equity dilution from the preferential allotment (~4.96% to promoter group) and the share-swap-based acquisition of the remaining 26% in Ayurvedagram, though loan-to-equity conversion improves the balance sheet. Short-term sentiment may be weak given deepening losses despite topline growth.